Mentions
Extended reach
Total likes
Video views
AI synopsis
Across the discussions, participants express excitement about the trial's findings, with phrases like 'game changer' and 'this is a big deal,' demonstrating their recognition of the potential impact on treatment strategies. They analyze specific data points such as hazard ratios and discussion about whether SGLT2 inhibitors could become a cornerstone therapy, showing deep engagement with the research and its clinical relevance.
Most discussions acknowledge the positive findings of the trial, highlighting its significance for HFpEF treatment.
Participants show strong curiosity and enthusiasm, emphasizing the trial's potential impact and relevance to current practice.
Many posts delve into details, citing specific statistics, trial design, and implications, reflecting deep engagement.
The discussions suggest the trial could lead to a paradigm shift in managing HFpEF and influence clinical guidelines significantly.
Cool name always in Cardiology! "Emperor" trial. Main benefit of SGLT2 drugs is reduced HOSPITALIZATION, not death. However this is what put SGLT2s as number ONE for HFpEF Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/Kr0pi0hi8O
The year is 2021 Based on the results of pts with T2D, the SGLT2i empagliflozin is tested for heart failure with normal ejection fraction, regardless of diabetes. And it works! EMPEROR-P https://t.co/10JMxP97EB (13/13)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitalización? ❌ Disminuye la Mortalidad? ❌ Disminuye la Mortalidad CV? ❌ Disminuye Hospitalización CV? ✅ WOOOOOOOW TENEMOS SUPER FARMACO!!!
Supplemental figure of EMPA-PRESERVED showing initial drop in eGFR. It is so interesting and instructive to reinforce this https://t.co/UFkva9aVyV https://t.co/rKmaQOaynq
Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprobada) en EMPEROR-Preserved. Reduce morbimortalidad al⬇️hospitalización x IC pero no demuestra⬇️de mortalidad (potencia insuficiente). https://t.co/xelmSxNOh3
2021: EMPEROR-Preserved Empagliflozin tested in pts with heart failure class II-IV and EF > 40%, regardless of diabetes. Result: decreased hospitalization for HF - CV death was part of the positive 1ary combined outcome. https://t.co/Kh1dKrUxFh 15/20
Prof Jörg Bojunga explains the optimal medication strategies for Type 2 Diabetes based on the National Guideline, discussing various drug classes and recent studies on insulin and cardiovascular outcomes.
Professor Stefan Anker presents key findings from the EMPEROR Preserved study, the first major randomized trial demonstrating a prognostic benefit of pharmacotherapy for patients with heart failure and preserved…
This week, John Mandrola MD discusses Tirzepatide vs semaglutide in obesity treatment, exploring their complexities and implications for heart failure outcomes. He also addresses the misuse of meta-analyses in heart…
This week in cardiology, John Mandrola MD discusses the ESC Wrapup Part II, focusing on the trial comparing intensive versus standard blood pressure treatment in older patients. Results indicate significant…
HEpEFに対するエンパグリフロジン(ジャディアンス)の有効性について ・LVEF>40のNYHA Ⅱ~ⅣのHFpEF患者を対象にエンパグリフロジン10mg/dayとプラセボ薬を比較 ・primary composit outcomeは心血管死or心不全による入院とされ、介入群で有意に減少(HR 0.79(0.69~0.90) https://t.co/KHRMx140to
@lE9BrvyUwLLVZIE こんばんは、初めまして。 EMPEROR-Preserved、DELIVERはダメですか？2023 ESC heart failure guidelineはHFpEFにもClass 1で推奨してたと思います。 https://t.co/1dxKVGoH4l https://t.co/aUSPcfD3IO
@ESodicoffMD Interesting. Both GLP1ra (https://t.co/zatcx5Ye9b) and SGLT2i work (https://t.co/NfYTsPWaVc)
2021: EMPEROR-Preserved Empagliflozin tested in pts with heart failure class II-IV and EF > 40%, regardless of diabetes. Result: decreased hospitalization for HF - CV death was part of the positive 1ary combined outcome. https://t.co/Kh1dKrDuDh
@DrFisioloco 1. https://t.co/66oxNdKcMS
#UCA #Repositorio #AccesoAbierto
@mmonaghan07 @drjohnm No. Neither cardiovascular death nor all cause mortality was reduced in this trial. Authors of EMPEROR trial used "composite outcome of hf hospitalisation AND cardiovascular death as a primary endpoint. Check table 2. ! ☺️ https://t.co/47Jwhynilx
@vmuecke_k Nein, ist er nicht: https://t.co/X4rw9SG6FI Tagestherapiekosten 2,40 für SGLT-2. Abgesehen davon halte ich es für ein starkes Stück, HFpEF als „keine echte Herzschwäche“ zu bezeichnen. Das sehen die Pat. mit Luftnot nämlich anders.
RT @SeeFisch: Cool name always in Cardiology! "Emperor" trial. Main benefit of SGLT2 drugs is reduced HOSPITALIZATION, not death. However…
@AgilaZainab @SeeFisch https://t.co/2wiUdi4mJS https://t.co/5LxNLvRScK
RT @SeeFisch: Cool name always in Cardiology! "Emperor" trial. Main benefit of SGLT2 drugs is reduced HOSPITALIZATION, not death. However…
RT @SeeFisch: Cool name always in Cardiology! "Emperor" trial. Main benefit of SGLT2 drugs is reduced HOSPITALIZATION, not death. However…
Cool name always in Cardiology! "Emperor" trial. Main benefit of SGLT2 drugs is reduced HOSPITALIZATION, not death. However this is what put SGLT2s as number ONE for HFpEF Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/Kr0pi0hi8O
RT @SeeFisch: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/Kr0pi0hi8O
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/Kr0pi0hi8O
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. | NEJM 2021 https://t.co/f3b3WrxDb3
@zainah_abdu @PromiseAlharbi https://t.co/5d58OFkKMJ
Among HF patients (class II–IV) with EF more than 40%. #Empagliflozin has shown 21% ( HR: 0.79) significantly lower relative risk in the composite of cardiovascular death or hospitalisation for heart failure.| Emperor-preserved trial | NEJM https://t.co/O2FiBxAMHL https://t.co/h35shfI6Jh
@MDCaspi @Booms_Hakofets @aljanosi @lamcardio Congrats, Dr Caspi and team. How does Empa fare in this model? https://t.co/BWQBhRklMV
RT @lE9BrvyUwLLVZIE: game changerと言われたNEJMのこちらの研究。EF<50%以下が33%もいるのに、どうしてSGLT2がHFpEFの入院を減らすと言えるんでしょうか
game changerと言われたNEJMのこちらの研究。EF<50%以下が33%もいるのに、どうしてSGLT2がHFpEFの入院を減らすと言えるんでしょうか
7/ Take-home pt: "If your EF is below 50%, SGLT2i, ARNI, BB & MRA, do that all together." What about HFpEF? Treat comorbidities (weight, OSA) & START SGL2i per @NEJM EMPEROR-preserved trial: https://t.co/V798U5P23w "SGL2is not just DM med, it's a ♥️ and kidney med as well." https://t.co/OnImpFKWPi
RT @clinicasac:
RT @clinicasac:
RT @clinicasac:
RT @clinicasac:
EF>40％の有症状心不全患者を対象にしたRCT、エンパグリフロジン群はプラセボ群と比べて心不全による入院を減らした。尿路感染症と低血圧は介入群で優位に多かった。 https://t.co/SrY4EnKPtA
EMPEROR-Preserved (https://t.co/hpDjczOEbR) showed reduction in the same primary outcome in pts with EF>40%
RT @mendesthiagob: 2021: EMPEROR-Preserved Empagliflozin tested in pts with heart failure class II-IV and EF > 40%, regardless of diabetes…
2021: EMPEROR-Preserved Empagliflozin tested in pts with heart failure class II-IV and EF > 40%, regardless of diabetes. Result: decreased hospitalization for HF - CV death was part of the positive 1ary combined outcome. https://t.co/Kh1dKrUxFh 15/20
4) EMPEROR-Preserved trial
RT @ckd_ce: 16) #Empagliflozin Outcome Trials in Patients w/ Chronic HF (EMPEROR) provided clear evidence of efficacy & safety for empa in…
16) #Empagliflozin Outcome Trials in Patients w/ Chronic HF (EMPEROR) provided clear evidence of efficacy & safety for empa in patients w/ #eGFR >/= 20 & HF #VisualAbstract by @whatsthegfr #EMPEROR_Preserved
DOI: 10.1056/NEJMoa2107038 https://t.co/N22Nskdf0C
RT @clinicasac:
RT @clinicasac:
RT @clinicasac:
RT @BertrandBio: @Mykalt45 @SamFazeli8 CV death were reduced by 9% (HR 0.91) in HF with preserved Ejection Fraction in EMPEROR-Preserved &…
@Mykalt45 @SamFazeli8 CV death were reduced by 9% (HR 0.91) in HF with preserved Ejection Fraction in EMPEROR-Preserved & by 8% (HR 0.92) in EMPEROR-Reduced https://t.co/WeNVA44oOT https://t.co/gmrDyiHRFk
RT @kaulcsmc: https://t.co/hXVzG2p9oq 1/ Congratulations to the EMPEROR-Preserved Trial Investigators and participants on this landmark tri…
RT @Fizz_DI: SGLT-2阻害薬の研究ざっくり流れ(8/8) ■EMPEROR-Preserved（N Engl J Med . 2021 Aug 27. doi: 10.1056/NEJMoa2107038. Online ahead of print. PMI…
RT @clinicasac:
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/zirbYEVOQA
@drjohnm This is relatively new one, but we finally get a solution https://t.co/eH1UubkK83
Journal Clubで初期の先生がEMPERORE-Preservedを取り上げてくれました。心不全に興味を持ってくれているようです。あつい！ Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/4KbF7cIE7a
Presented my first journal club of APPEs on the EMPEROR-Preserved study today, including the 2022 HFpEF update
RT @Nephro_Sparks: Supplemental figure of EMPA-PRESERVED showing initial drop in eGFR. It is so interesting and instructive to reinforce th…
RT @Nephro_Sparks: Supplemental figure of EMPA-PRESERVED showing initial drop in eGFR. It is so interesting and instructive to reinforce th…
https://t.co/qHhPgm9rkn
RT @Nephro_Sparks: Supplemental figure of EMPA-PRESERVED showing initial drop in eGFR. It is so interesting and instructive to reinforce th…
Supplemental figure of EMPA-PRESERVED showing initial drop in eGFR. It is so interesting and instructive to reinforce this https://t.co/UFkva9aVyV https://t.co/rKmaQOaynq
RT @cardiomet_CE: 37) So, where were we? Oh yes, trials ➡️ benefit of #SGLT2i's in #T2DM, #chronic #HFrEF, #AHF, & #CKD (the latter not cov…
37) So, where were we? Oh yes, trials ➡️ benefit of #SGLT2i's in #T2DM, #chronic #HFrEF, #AHF, & #CKD (the latter not covered in this edition). #SGLT2i has now been tested in #chronic #HFpEF, in #EMPEROR_PRESERVED. Here you can see the trial design (
RT @cpgale3: @mvaduganathan @ShashankSinhaMD @drjohnm @theheartorg @djc795 @ATSandhu @ChristosArgyrop @David_Ouyang You’ve omitted the row…
@mvaduganathan @ShashankSinhaMD @drjohnm @theheartorg @djc795 @ATSandhu @ChristosArgyrop @David_Ouyang You’ve omitted the row detailing the effects on cardiovascular death. Death from cardiovascular causes occurred in 219 patients (7.3%) in the empagliflozin group and in 244 patients (8.2%) in the placebo group (hazard ratio, 0.91; 95% CI, 0.76 to 1.09) https://t.co/wASI45qRCV
36) EMPEROR-Preserved has recently reported (
ACP Journal Club's excellent analysis of the EMPEROR-Preserved trial that demonstrated CV outcome benefits of SGLT-2 inhibitors in HFpEF patients: https://t.co/kECHxEJEI3 Original trial: https://t.co/zfiqMC5Exy #Cardiology #CardioTwitter #MedTwitter #EBM https://t.co/fyv9MwDYTN
sorry I meant EMPEROR-PRESERVED in first tweet https://t.co/gDTIoKwZLS
Empagliflozina en IC Fey preservada
RT @IshiyakuApp: ジャディアンスの主要試験 【EMPEROR-Preserved試験】 NYHA分類で2～4度の心不全症状があり、LVEF≧40％、NT-proBNP≧300pg/mLの成人の慢性心不全患者（HFpEF）に対して、プラセボと比較して、心血管死亡ま…
El estudio es impecable en cuanto a su diseño (aleatorización, enmascaramiento, análisis por intención de tratar, tamaño muestral,...) En fin. Que es un buen estudio. 3/9 https://t.co/FdRfJrRR97
Trial leading to expanded indication https://t.co/rfLao4Jib7
2022 AHA/ACC/HFSA Heart Failure Guideline - SGLT2 inhibition should be considered in heart failure with preserved ejection fraction... now the door is open for further exploration
The 2021 trial every GP should, but doesn’t know @GPSynergy @RACGP https://t.co/MaMiJG9KTi
Klīniskajos pētījumos apstiprināts, ka zāles par 21% samazina mirstības&hospitalizācijas relatīvo risku neatkarīgi no sirds izsviedes frakcijas vai diabēta esamības. Tā ir iespēja palīdzēt uzlabot dzīvildzi un veselību daudziem sirds mazspējas pacientiem. https://t.co/O7RCnDff8P
RT @IshiyakuApp: ジャディアンスの主要試験 【EMPEROR-Preserved試験】 NYHA分類で2～4度の心不全症状があり、LVEF≧40％、NT-proBNP≧300pg/mLの成人の慢性心不全患者（HFpEF）に対して、プラセボと比較して、心血管死亡ま…
ジャディアンスの主要試験 【EMPEROR-Preserved試験】 NYHA分類で2～4度の心不全症状があり、LVEF≧40％、NT-proBNP≧300pg/mLの成人の慢性心不全患者（HFpEF）に対して、プラセボと比較して、心血管死亡または心不全入院の初回イベントを21%有意に低下させた。 https://t.co/ROH2GCqlNZ
@dr_komugi_ Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/l8vRU64Mta すみません、先ほどコピペミスしました
Antihyperglykämische Therapie bei Typ 2 DM - Prof Bojunga (Frankfurt a... https://t.co/jJLWPY3efZ via @YouTube "Menschen töten für Kohlenhydrate" mit @StephanSchirme1 @MarcusSaemann
RT @mendesthiagob: The year is 2021 Based on the results of pts with T2D, the SGLT2i empagliflozin is tested for heart failure with normal…
RT @mendesthiagob: The year is 2021 Based on the results of pts with T2D, the SGLT2i empagliflozin is tested for heart failure with normal…
RT @mendesthiagob: The year is 2021 Based on the results of pts with T2D, the SGLT2i empagliflozin is tested for heart failure with normal…
RT @mendesthiagob: The year is 2021 Based on the results of pts with T2D, the SGLT2i empagliflozin is tested for heart failure with normal…
The year is 2021 Based on the results of pts with T2D, the SGLT2i empagliflozin is tested for heart failure with normal ejection fraction, regardless of diabetes. And it works! EMPEROR-P https://t.co/10JMxP97EB (13/13)
@AtulBaliMD @tony_breu @bmj_latest The lack of options in HFpEF is a source of major frustration though, isn't it? EMPEROR-Preserved was nice, but still quite a big NNT. https://t.co/XEnDdD1gjx
EMPEROR-Preserved（ PMID:34449189）の影響を反映するにはまだ、早いよってことですかね。 https://t.co/uzIvzRunM4 https://t.co/Aws2uTf5tO https://t.co/Sqfw5rXUlp
And EMPEROR RCT Empagiflozin finally an Rx which improves outcomes in heart failure w preserved Ejection Fraction seems a big deal https://t.co/ueaVwQEz1P
@SeguraCardio @JCardFail @robmentz @dranulala @j_alvarezgarcia @paomorejon @HFpEF @gcfmd @ShelleyZieroth @IcyfaSemi @SIAC_cardio What about empagliflozin in the pharmacologic therapy box? It's all the rage nowadays, regardless of diabetes status! #medtwitter #endotwitter https://t.co/oPkzkaZ1Uo
RT @MGol_MD: @SeguraCardio @JCardFail @robmentz @dranulala @j_alvarezgarcia @paomorejon @HFpEF @gcfmd @ShelleyZieroth @IcyfaSemi @SIAC_card…
@SeguraCardio @JCardFail @robmentz @dranulala @j_alvarezgarcia @paomorejon @HFpEF @gcfmd @ShelleyZieroth @IcyfaSemi @SIAC_cardio Great overview! Maybe as therapeutic add-ons, titrating down beta-blockers (if no other reasons of use such as Afib etc) and SGLT2-Inhibitor utilization. Sources: 1) https://t.co/TaOsQmEdWT 2) https://t.co/NEMZHPFoWc
[
RT @atscommunity: Join @ATS_PC on Friday, December 17 at 12PM ET for a Journal Club on the article: “Empagliflozin in Heart Failure with a…
RT @rjbernardoMD: @ATS_PC is pleased to announce their next JC on
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/VYu1MoBU0E
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
RT @EmilioAlegre1: Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprob…
Hemos analizado EMPAGLIFLOZINA en pac. con insuficiencia cardiaca y fracción de eyección preservada (indicación no aprobada) en EMPEROR-Preserved. Reduce morbimortalidad al⬇️hospitalización x IC pero no demuestra⬇️de mortalidad (potencia insuficiente). https://t.co/xelmSxNOh3
RT @atscommunity: Join @ATS_PC on Friday, December 17 at 12PM ET for a Journal Club on the article: “Empagliflozin in Heart Failure with a…
RT @atscommunity: Join @ATS_PC on Friday, December 17 at 12PM ET for a Journal Club on the article: “Empagliflozin in Heart Failure with a…
Join @ATS_PC on Friday, December 17 at 12PM ET for a Journal Club on the article: “Empagliflozin in Heart Failure with a Preserved Ejection Fraction” recently published in the New England Journal of Medicine. Register here: https://t.co/cWJZl0i9oF https://t.co/YTKHHgfeYa
RT @rjbernardoMD: @ATS_PC is pleased to announce their next JC on
RT @JuliaSellerm:
RT @rjbernardoMD: @ATS_PC is pleased to announce their next JC on
RT @rjbernardoMD: @ATS_PC is pleased to announce their next JC on
@ATS_PC is pleased to announce their next JC on
RT @JuliaSellerm:
RT @JuliaSellerm:
RT @JuliaSellerm:
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/ONKTJCuHEO
RT @CardioNerdsJC: To get situated: check out this powerful
RT @sarahhudsonuk:
RT @AKronbichler: Markus@Home hat Prof. Stefan Anker zum Thema SGLT2i bei erhaltener LV-Funktion interviewt. Hier der Link zum Video: https…
RT @AKronbichler: Markus@Home hat Prof. Stefan Anker zum Thema SGLT2i bei erhaltener LV-Funktion interviewt. Hier der Link zum Video: https…
Markus@Home hat Prof. Stefan Anker zum Thema SGLT2i bei erhaltener LV-Funktion interviewt. Hier der Link zum Video: https://t.co/w68367r1aQ Sehr empfehlenswert @gunnar_heine @anjascheuer
RT @floriancustodis: tune in tonight
RT @floriancustodis: tune in tonight
RT @floriancustodis: tune in tonight
tune in tonight
RT @Drroxmehran: ✅#EMPEROR-Preserved at #ESCCongress: Empagliflozin ⬇️the combined risk of CV ☠️ or hospitalization for HF in pts w/ HFpEF…
RT @Dr_Manito: @ValleAlfonso @AHAScience @secardiologia @radcliffeCARDIO @DrMarthaGulati @mvaduganathan @paomorejon @MKIttlesonMD @rafavida…
RT @Dr_Manito: @ValleAlfonso @AHAScience @secardiologia @radcliffeCARDIO @DrMarthaGulati @mvaduganathan @paomorejon @MKIttlesonMD @rafavida…
RT @Dr_Manito: @ValleAlfonso @AHAScience @secardiologia @radcliffeCARDIO @DrMarthaGulati @mvaduganathan @paomorejon @MKIttlesonMD @rafavida…
RT @Dr_Manito: @ValleAlfonso @AHAScience @secardiologia @radcliffeCARDIO @DrMarthaGulati @mvaduganathan @paomorejon @MKIttlesonMD @rafavida…
RT @Dr_Manito: @ValleAlfonso @AHAScience @secardiologia @radcliffeCARDIO @DrMarthaGulati @mvaduganathan @paomorejon @MKIttlesonMD @rafavida…
@ValleAlfonso @AHAScience @secardiologia @radcliffeCARDIO @DrMarthaGulati @mvaduganathan @paomorejon @MKIttlesonMD @rafavidalperez @yulnunezvill @SantosGallegoMD @JTLLERGO @gcfmd @josejgdnews With the results of EMPULSE, New data of SOLOIST, EMPEROR-Preserved + Analysis of Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50%, a new update of the HFA-ESC HF guidelines is necessary
【S22-5】サブグループ解析上、LVEF≥60%、70歳未満では差がなかった。 https://t.co/IDEhTPkLPN #jsphcs2021
#071 Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med 2021;385:1451-61. EMPEROR-Preserved試験 HFpEFにエンパグリフロジン追加で、心血管死と心不全入院の複合エンドポイントを改善する
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/PjEjQYh04q
RT @KentoSonoda: Important paper to review the latest evidence about management of HFpEF. https://t.co/MTFpdqhwVT Anker SD, Butler J, Filip…
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/5eiTqT9Rk7
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/2TBexCrzqt
RT @CiCPNancy: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | @NEJM @INICRCT #CardiovascularResearch #cardiovascular…
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/9bazVt57uu
N Engl J Med 2021;385:1451-61. Empagliflozin in Heart Failure with a Preserved Ejection Fraction EFが良くなるほど効果が低下する、HFpEFに良く効くとは言い難い https://t.co/bWB5dDuT1U
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | @NEJM @INICRCT #CardiovascularResearch #cardiovascular https://t.co/D8pN5L3MIr
RT @svhmedres: We concluded our first online journal club @NEJMres360 on the paradigm-shifting EMPEROR-Preserved trial last week! We are ve…
RT @svhmedres: We concluded our first online journal club @NEJMres360 on the paradigm-shifting EMPEROR-Preserved trial last week! We are ve…
We concluded our first online journal club @NEJMres360 on the paradigm-shifting EMPEROR-Preserved trial last week! We are very grateful to the authors, Prof. Stefan D. Anker and Dr. Javed Butler for their participation in this exciting discussion: https://t.co/04pvDJjgaq https://t.co/D11UmcAuaj
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
pEFの治療戦略を変えるのもそうだし、もはやSGLT2をnon-DMに処方していく変化はクソデカいと思います。 2021年ベスト重要論文！ Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/Vp2gPHpgf2
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM LVEF >40% to <50% no. (%) 995 (33.2) HR：0.71 (0.57–0.88)、 LVEF ≥50% to <60%no. (%) 1028 (34.3) HR：0.80 (0.64–0.99)、 LVEF ≥60% no. (%) 974 (32.5) HR：0.87 (0.69–1.10)、 https://t.co/zikq1s0ySQ
RT @JohnHRandall1: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/x2epIPBRZZ
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/x2epIPBRZZ
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
LVEF 40%以上の心不全患者におけるSGLT2阻害薬(エンパグリフロジン)の効果✍️ Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/2UqhrBir2D
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
RT @paselsab: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitaliza…
Important paper to review the latest evidence about management of HFpEF. https://t.co/MTFpdqhwVT Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461 from @NEJM #MedTwitter #MedEd https://t.co/arMZREmF0n
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/zc0Ygussw1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461 Disminuye la Hospitalización? ❌ Disminuye la Mortalidad? ❌ Disminuye la Mortalidad CV? ❌ Disminuye Hospitalización CV? ✅ WOOOOOOOW TENEMOS SUPER FARMACO!!!
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/f2gm2QiYp7
RT @irodriguezpenin: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/sMYmjJXCsE
EMPEROR-Preserved: Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/vmbtN8SnhN
RT @irodriguezpenin: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/sMYmjJXCsE
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/sMYmjJXCsE
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/bBRq6bKapD
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/oHRffqXNRN
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | @NEJM https://t.co/2anqrLzqlg
RT @JohnHRandall1: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/1O2SvxkBZ6
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/1O2SvxkBZ6
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/UcAXHnlOVC
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/HtEmEKaOFJ
RT @AlexGtrzD: NNT 30.03 (20.1-63.7) Is it enough for you? Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https:…
Regardless of the presence or absence of diabetes: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/UlyVeS1Iz6
RT @Yohei_Kanzawa: 改めて今週号はEMPEROR-preserved。 HFpEFの患者さんのときに頭がよぎりますが当科ではDMがあったとしてもSGLT2i導入の難しい人がほとんど。。。 Empagliflozin in Heart Failure with…
改めて今週号はEMPEROR-preserved。 HFpEFの患者さんのときに頭がよぎりますが当科ではDMがあったとしてもSGLT2i導入の難しい人がほとんど。。。 Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/cdi3MFSCll
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/xHIlePk5jn
RT @xxxichiroxxx_ID: Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/GCM5gAsm4W エンパグリフロジンは，糖尿病の有無にかか…
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/GCM5gAsm4W エンパグリフロジンは，糖尿病の有無にかかわらず，駆出率が維持されている心不全患者の心血管死または心不全による入院の複合リスクを低減した．
@NEJMres360 Journal Club with Saint Vincent Hospital Internal Medicine Residency Program on Empagliflozin in Heart Failure With a Preserved Ejection Fraction https://t.co/VDxoRyieij
@djc795 @rwyeh @jd_wilko OK, here's one of the first big newsmaking cardiology trials that I could think of from the past year: https://t.co/85WKjpLFVN
Empagliflozin in Heart Failure with a Preserved Ejection Fraction, Dr. Stefan Anker- Charité - University of Medicine, Berlin @ChariteBerlin #HeartFailure #Cardiology #Research https://t.co/e0stMW1Lfk https://t.co/ABeKNhKsPo
Podcast- @ChariteBerlin #HeartFailure #Cardiology #Research Dr. Stefan Anker- Charité - University of Medicine, Berlin- Empagliflozin in Heart Failure with a Preserved Ejection Fraction Link to Audio- https://t.co/WbnXiaWJyT https://t.co/hflP2Y4w40
@ChariteBerlin #HeartFailure #Cardiology #Research Dr. Stefan Anker- Charité - University of Medicine, Berlin- Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/QUVDDxaz3k https://t.co/blVplN4fAd
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/8VRC877Oop
RT @joseansatue: @Miguel_A_Maria @Sociedad_SEMI Emperor Preserved, más bien
@Miguel_A_Maria @Sociedad_SEMI Emperor Preserved, más bien
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/jQTTpEyokE
Empagliflozin in Heart Failure with a Preserved Ejection Fraction Stefan D Anker et al. N Engl J Med. 2021. https://t.co/FUOqptcAOT
RT @AsamaCardiology: 糖尿病薬のSGLT2阻害薬で，心不全患者さんの心血管死や心不全入院を減らしたと報告されました 糖尿病の有無とは関係ありません 日本でも増加している心不全患者さんに朗報です 我々も積極的にSGLT2阻害薬を使用していますが，単に糖尿病薬…
糖尿病薬のSGLT2阻害薬で，心不全患者さんの心血管死や心不全入院を減らしたと報告されました 糖尿病の有無とは関係ありません 日本でも増加している心不全患者さんに朗報です 我々も積極的にSGLT2阻害薬を使用していますが，単に糖尿病薬でなく，心不全薬となってきました https://t.co/Q6hiq9cfUX
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM https://t.co/RQoSihFqHl
RT @EmilioAlegre1: Creo que la medida clave de eficacia, viendo en mortalidad CV/no CV que no hay beneficio, es una ⬇️ del 1,7% en los hosp…
RT @Dr_mandheling: SGLT2阻害薬は糖尿病の有無に関わらず、HFpEF患者の予後を改善するかもしれない。 心不全による入院だけでなく、心血管死も減らす可能性。 Stefan D Anker, et al ; Empagliflozin in Heart…
RT @Dr_mandheling: SGLT2阻害薬は糖尿病の有無に関わらず、HFpEF患者の予後を改善するかもしれない。 心不全による入院だけでなく、心血管死も減らす可能性。 Stefan D Anker, et al ; Empagliflozin in Heart…
Creo que la medida clave de eficacia, viendo en mortalidad CV/no CV que no hay beneficio, es una ⬇️ del 1,7% en los hospitalizados anuales por IC (4,6 vs. 6,3%). En mi opinión, relevante aunque modesto. https://t.co/Z3p9vOBlCG https://t.co/2y4rVVonbo
SGLT2阻害薬は糖尿病の有無に関わらず、HFpEF患者の予後を改善するかもしれない。 心不全による入院だけでなく、心血管死も減らす可能性。 Stefan D Anker, et al ; Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Aug 27. doi: https://t.co/nKb1ddIECA
【RCT】NYHA分類II-IVの駆出率が40%を超える心不全患者へのエンパグリフロジン投与は、プラセボ投与と比較して、心血管死亡、心不全による入院の複合転帰のリスクを減少させた。 #ペ読 https://t.co/IDEhTPkLPN
SGLT2阻害薬が左室駆出率の保たれた心不全（HFpEF）に有効性を示す
Trending on PubMed: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. https://t.co/ZxakSU7rLa
What we stated in 2019: Proof: Empagliflozin (EMBA)-based therapy for Cardiac repair and myocardial infarction: 15/2/2019, https://t.co/Jbx2YNwXtE What was published in 2021 in NEJM: Empagliflozin reduced the combined risk of cardiovascular death https://t.co/BlIeCscwx3
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/UAV9I2cjja "Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure." Proof of principle: https://t.co/ax1fYKlmgV https://t.co/vQqjKiJFgu
Encouraging for SGLT2i therapy: Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/9PoBeInrWq Empagliflozin⬇️the combined risk of outcome (CV death or hospitalization for HF) in this population, regardless of the presence or absence of diabetes
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/t3xKnkKkzd
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/varcqpqxt8 PubMedも置いときますね． 糖尿病患者は約50%含まれています．
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://t.co/w5Ss9RvcP3 https://t.co/37R1qJC1Nd
SS